Carlsmed Announces first corra™ personalized Cervical Plating Procedure
Rhea-AI Summary
Carlsmed (Nasdaq: CARL) announced the first personalized cervical plating procedure using the corra™ Cervical Plating System on Feb. 18, 2026.
The procedure, performed by Dr. Aaron Clark at UCSF, begins a clinical evaluation ahead of a planned commercial launch of corra™ later in 2026 and highlights integration with aprevo® planning and interbody devices.
Positive
- Completed first personalized corra™ cervical plating procedure on Feb. 18, 2026
- Clinical evaluation initiated at UCSF to inform product refinement
- corra™ integrates with aprevo® planning and interbody devices for patient-specific fit
Negative
- No published clinical outcomes yet; data will inform further refinement
- Commercial launch only anticipated later in 2026, timing remains uncertain
News Market Reaction – CARL
On the day this news was published, CARL gained 5.57%, reflecting a notable positive market reaction. Argus tracked a peak move of +5.0% during that session. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $18M to the company's valuation, bringing the market cap to $332M at that time.
Data tracked by StockTitan Argus on the day of publication.
Market Reality Check
Peers on Argus
CARL was up 2.1% while key peers mostly traded lower today (e.g., OPRX -3.83%, SY -4.62%, NRC -0.41%, SPOK -0.15%). TALK was a notable outlier, gaining 1.86%.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 11 | Earnings date set | Neutral | -5.8% | Announcement of date for Q4 and full-year 2025 financial results release. |
| Feb 10 | New lumbar procedure | Positive | -0.1% | First aprevo® lumbar bi-lateral posterior fusion procedure at University of Colorado Hospital. |
| Jan 12 | Prelim 2025 revenue | Positive | +13.8% | Preliminary Q4 and full-year 2025 revenue with strong year-over-year growth and user expansion. |
| Jan 06 | 2-year lumbar data | Positive | +2.9% | Peer-reviewed data showing reduced 2-year mechanical-complication revision rates versus conventional implants. |
| Dec 16 | Conference participation | Neutral | +0.0% | Planned presentation and one-on-one investor meetings at a major healthcare conference. |
Recent product and clinical data updates have generally seen modestly positive to strong positive reactions, while scheduling and earnings-date announcements have sometimes coincided with weakness.
Over the last few months, Carlsmed has reported strong preliminary 2025 revenue growth, with Q4 revenue around $15.2M and full-year revenue around $50.5M, plus surgeon adoption gains. Peer-reviewed 2-year lumbar data showed markedly lower revision rates versus stock implants, and the company has continued rolling out new aprevo® spine procedures. An earnings date announcement on Feb 11 preceded a negative move, contrasting with the positive reaction to revenue preliminaries. Today’s personalized cervical plating milestone extends the trend of product and clinical expansion updates.
Market Pulse Summary
The stock moved +5.6% in the session following this news. A strong positive reaction aligns with Carlsmed’s pattern of favorable responses to product and data milestones, such as earlier revenue and clinical updates. However, shares remained well below the 52-week high and the 200-day MA of $13.25, underscoring that the stock had been under technical pressure. Investors monitoring sustainability would typically watch subsequent clinical evaluation data, commercialization progress for cervical solutions, and upcoming 2025 earnings disclosures.
Key Terms
anterior cervical discectomy and fusion medical
acdf medical
biomechanics medical
digital surgery ecosystem technical
AI-generated analysis. Not financial advice.
The corra™ Cervical Plating System marks the debut of Carlsmed's patient-specific fixation portfolio
CARLSBAD, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the first personalized cervical plating procedure using the corra™ Cervical Plating System, the latest addition to its portfolio of personalized spine surgery solutions. The procedure, which was performed by Dr. Aaron Clark at the University of California San Francisco (UCSF), represents an important milestone as the Company prepares for the planned commercial launch of the corra™ system later this year.
“We’re excited to expand our personalized cervical offerings following the recent launch of our aprevo® Cervical Interbody System,” said Mike Cordonnier, Chairman and CEO of Carlsmed. “This first procedure and the commencement of the clinical evaluation is an important step in validating our technology in a real-world setting. We developed corra™ to address unmet needs in cervical spine surgery, and we remain committed to delivering solutions designed to support surgeons, improve alignment precision and enhance patient outcomes through truly personalized design.”
The corra™ Cervical Plating System is designed to stabilize the cervical spine during fusion procedures using patient-specific plates tailored to each individual’s anatomy and surgical plan. Utilizing Carlsmed’s digital surgery ecosystem, key anatomical aspects including screw positioning and plate curvature are tailored pre-operatively to each vertebral level, helping support consistent fixation and precise alignment for Anterior Cervical Discectomy and Fusion (ACDF) procedures. When used in conjunction with the aprevo® cervical planning and interbody fusion devices, the corra™ Personalized Plating System can provide anatomical fit and fixation for patients.
“Cervical plates play a critical role in stabilizing fusion constructs, and extending personalization to cervical fixation can enable more precise plate positioning and screw trajectory,” said Dr. Aaron Clark of UCSF. “Designing each plate around patient-specific anatomy and alignment objectives has the potential to reduce intraoperative contouring and support more accurate execution of the preoperative plan. This precision reinforces confidence in the biomechanics of each patient’s construct and may help mitigate risks associated with adjacent-level stress that can contribute to postoperative symptoms and revision surgery following ACDF procedures.”
Data from the clinical evaluation will inform continued product refinement as Carlsmed prepares for broader market introduction. The Company expects to conduct additional evaluations in the coming months and anticipates commercial launch later this year.
About Carlsmed
Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond.
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects, including statements about the timing of the commercial launch of the Company’s corra™ system, the potential of the Company’s products, the ability of the Company’s products to improve patient outcomes, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including such important factors as are set forth under the caption “Risk Factors” in Carlsmed’s Registration Statement on Form S-1 on file with the U.S. Securities and Exchange Commission. The forward-looking statements included in this press release represent Carlsmed’s views as of the date of this press release. Carlsmed anticipates that subsequent events and developments will cause its views to change. However, while Carlsmed may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Carlsmed’s views as of any date subsequent to the date of this press release.
Investor Relations
Caroline Corner, PhD
IR@Carlsmed.com
Media
LeAnn Burton
Senior Director Brand Marketing
LBurton@Carlsmed.com
FAQ
What did Carlsmed (CARL) announce about the corra™ Cervical Plating System on Feb. 18, 2026?
Who performed the first corra™ personalized cervical plating procedure for CARL and where?
How does the corra™ Cervical Plating System work with aprevo® for CARL patients?
When does Carlsmed (CARL) plan to commercially launch the corra™ system?
What potential surgical benefits does corra™ offer for ACDF procedures according to CARL?
Will there be clinical data available immediately after the first corra™ procedure for CARL investors?
